Let's move on to the mixed agonists, antagonists class of
drugs. So, these are harder to understand,
but this is where the receptors start to come into play.
Let's talk about Nubain. Now, Nubain will not antagonize
other opioid drugs. It may still be addictive however.
It is an agonist at the kappa receptor
and an antagonist at the mu receptor.
What this gives us is a "respiratory ceiling".
So, what that means is, is that even if you give
very high doses of this drug, there is minimal risk of
respiratory depression. There is also a lower risk of addiction.
And in fact, this particular agent was taken off the
class II list of controlled substances by the FDA.
It is also used for morphine induced itching or pruritus,
so that you don't get as many histamine reactions
from this medication. Now, you're unlikely to be
tested on this drug, at least in the past,
I don't know if this is going to be on the exams
in the future, it's relatively new,
it is something that we're starting to use
more and more in clinical practice.
So although it hasn't been tested on extensively
in the past, just be aware of it
and keep your eyes and ears open.
Now, this is another morphine analogue.
It is a semisynthetic partial agonist.
Uses are in opioid addiction with methadone,
for use in some pain management patients,
it is found to be effective in
refractory depression as well,
and there is a particular condition called
neonatal abstinence syndrome.
This is why this drug is on our list because
it is used in those patients who are neonates,
who are survivors of mothers who are addicted to morphine.
It is currently being studied, by the time you're
watching this video, the study will be out,
and we will know if we were going to be using it
in clinical practice or not.
So, it's very new, but I think that it holds great promise,
and I believe that the studies will be good.
Going on, in terms of it's activity at different receptor
sites at the mu receptor, it's a weak partial agonist.
Remember that it binds very tightly so it will
stay bound to that receptor for a long time.
In terms of the kappa receptor, it's a weak agonist,
and in terms of the delta receptor, it's an antagonist.
Now, we do have an unusual concern about this medication is
because it binds very tightly to the mu receptor,
it will not respond to additional stronger opioids
except for sufentanil or Sufenta.
Why is this a problem? If patients have
breakthrough pain while they're on this medication,
we can't add another opioid agonist.
Now, Sufenta is the most powerful of the opioids.
You're not going to get tested on it,
it's about 100 times more powerful than fentanyl,
and about 800 times more powerful than morphine.
It's an extremely strong agent,
and it's used almost exclusively in anesthesia.
Alright, the antagonists, naloxone.
Naloxone is also called Narcan.
I do think it's important to know the trade name
because in the crash kits or in the code kits,
it will often be labelled Narcan
instead of its chemical name naloxone.
So, it is worthwhile for clinical practice to know its
trade name, for your exam it's not as important.
It is a synthetic mu receptor pure
competitive antagonist or blocker.
We use it for blocking or reversing toxicity from opioids.
It may be used in conjunction with the opioid,
to prevent excessive mental and respiratory depression.
Side effects. In patients on opioids, you may cause
swelling. Now patient who aren't taking opioids
shouldn't have any side effects. But there is actually
something that is very interesting that we've started to see.
It's called placebo pain control syndrome. Now, patients who
let's say twisted an ankle but don't really feel much pain,
when you give them naloxone, they start to feel pain.
And we believe it's because naloxone is blocking the
endorphin related pain control that
the body is producing on its own.
So sometimes you can get an increase in pain
when you're using naloxone.
Okay, there you have it.
These are all of the opioid analgesics.
Just have a look at the listed names and medications,
and just try to remember what kind of receptors they block.